A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Status:
Terminated
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal
injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe
non-proliferative diabetic retinopathy (NPDR), to induce total posterior vitreous detachment
(PVD) in order to reduce the risk of disease progression to proliferative diabetic
retinopathy (PDR).